BMC Cancer最新文献

{"title":"Chidamide impedes glycolysis but increases ferroptosis and cisplatin sensitivity of lung cancer cells through downregulating USP35.","authors":"Kunjie Wang, Lin An, Aimin Zang, Yue Huo","doi":"10.1186/s12885-025-14925-z","DOIUrl":"10.1186/s12885-025-14925-z","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1504"},"PeriodicalIF":3.4,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival risk stratification of 2021 WHO glioblastoma by MRI radiomics and biological exploration.","authors":"Yangyang Li, Wenji Xu, Chunjuan Zhao, Jie Zhang, Zhiyi Zhang, Pengxin Shen, Xiaochun Wang, Guoqiang Yang, Jiangfeng Du, Hui Zhang, Yan Tan","doi":"10.1186/s12885-025-14906-2","DOIUrl":"10.1186/s12885-025-14906-2","url":null,"abstract":"<p><strong>Background: </strong>There is variability in overall survival among 2021 World Health Organization isocitrate dehydrogenase wild type glioblastoma (IDH-wt GBM) patients. The aim of the study was to develop a combined model for stratifying survival risk in IDH-wt GBM and explore the biological foundation.</p><p><strong>Methods: </strong>A total of 369 IDH-wt GBM patients were retrospectively collected: 273 patients from three local hospitals (training set: n = 192, testing set: n = 81) and 96 patients from the TCIA database (validation set). Radiomics features from tumor and peritumoral edema in preoperative CE-T1WI and T2FLAIR were extracted. Univariate and least absolute shrinkage and selection operator Cox regression analyses selected significant radiomics features to construct radiomics model, while univariable and multivariable analyses identified clinical risk factors for the clinical model. High-risk and low-risk patients from radiomics and clinical model underwent subgroup analysis. The combined model was constructed using the Random Survival Forest model. Additionally, differentially expressed genes between combined high-risk and low-risk groups were identified, with enrichment analyses exploring their biological mechanisms.</p><p><strong>Results: </strong>The radiomics model categorizes patients into high-risk and low-risk groups with superior performance (C-index: 0.762/0.715/0.690 for training/testing/validation sets) compared to the clinical model (C-index: 0.700/0.656/0.643). The combined model demonstrates the highest value in survival risk stratification (C-index: training/testing/validation sets: 0.788/0.725/0.709). The activation of Gamma-aminobutyric acid (GABA) receptor-related pathways is closely associated with malignant progression and prognosis of IDH-wt GBM.</p><p><strong>Conclusions: </strong>The radiomics model might be a new prognostic biomarker for IDH-wt GBM. The combined model shows an approximately 12.57% improvement of stratification ability over the clinical model. Additionally, the significant activation of GABA receptor-related pathways may be a biological feature of combined high-risk IDH-wt GBM.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1505"},"PeriodicalIF":3.4,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression and prognostic value of MCM2 in type B thymomas.","authors":"Xin Du, Jian Cui, Xintao Yu, Dingfang Cao, Ying Zhang, Lei Yu, Shanqing Li","doi":"10.1186/s12885-025-14807-4","DOIUrl":"10.1186/s12885-025-14807-4","url":null,"abstract":"<p><strong>Background: </strong>Thymic epithelial tumors (TETs) are the most common mediastinal malignancies, lacking reliable prognostic biomarkers. This study aimed to identify a potential prognostic marker for TETs.</p><p><strong>Methods: </strong>mRNA microarray analysis of 30 tumor and peritumoral tissues identified differentially expressed genes (DEGs). Hub genes were selected via protein-protein interaction (PPI) analysis, with MCM2 chosen as the target gene. Survival and enrichment analyses were performed, and a validation cohort assessed MCM2's association with prognosis and clinicopathological features.</p><p><strong>Results: </strong>Seven hundred thirty-four DEGs were identified, with MCM2 significantly associated with prolonged progression-free survival (PFS) (HR = 0.17; 95% CI: 0.05-0.54; p = 0.003) and identified as an independent risk factor for PFS (HR = 0.26; 95% CI: 0.08-0.91; p = 0.035). MCM2 expression decreased from type B1 to B3 thymomas.</p><p><strong>Conclusions: </strong>MCM2 is an independent prognostic factor for TETs, with higher expression linked to better PFS and decreasing expression across B-type thymomas, suggesting its role as a favorable prognostic marker.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1506"},"PeriodicalIF":3.4,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145224974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Importance of PERK pathway modulation on colorectal cancer management: a systematic review.","authors":"Marzieh Nemati, Sanaz Dastghaib, Zahra Hosseinzadeh, Mina Molayem, Morvarid Siri, Bahareh Ebrahimi, Zohreh Bagheri","doi":"10.1186/s12885-025-14952-w","DOIUrl":"10.1186/s12885-025-14952-w","url":null,"abstract":"<p><strong>Background: </strong>The protein kinase RNA-like endoplasmic reticulum kinase (PERK) branch of the Unfolded Protein Response (UPR) plays a complex and context-dependent role in the colorectal cancer (CRC). While some studies indicate that PERK activation suppresses tumor growth by inducing apoptosis and limiting proliferation, others suggest that it may promote tumor progression by supporting cancer cell survival under stress. This systematic review aims to clarify the dual role of PERK signaling in CRC and evaluate its potential as a therapeutic target.</p><p><strong>Methods: </strong>We included full-text English-language studies investigating the role of PERK signaling in CRC using in vitro and/or animal models. Studies on non-CRC malignancies or unrelated mechanisms were excluded. Searches were conducted in PubMed, Web of Science (WOS), and Scopus using relevant keywords.</p><p><strong>Results: </strong>A total of 395 articles were initially identified. After removing duplicates (n = 173), review articles (n = 11), and unrelated studies (n = 66), 45 studies met the inclusion criteria. Most of these (n = 36) used in vitro models, with the HCT-116 cell line being the most frequently used (n = 19). While most studies (n = 36) reported anti-tumorigenic effects associated with PERK activation, several identified conditions under which PERK signaling may support tumor progression. These conflicting findings may be attributed to differences in experimental models, PERK modulation strategies, and endoplasmic reticulum stress induction methods.</p><p><strong>Conclusions: </strong>This review highlights the dual and context-dependent nature of PERK pathway activation in CRC. Although PERK often appears to exert tumor-suppressive effects, evidence also points to its tumor-promoting potential under certain conditions. A nuanced understanding of these roles is crucial for developing PERK-targeted therapies in CRC.</p><p><strong>Trial registration: </strong>This systematic review has been registered in PROSPERO (International Prospective Register of Systematic Reviews) with the registration number CRD42023241342.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1502"},"PeriodicalIF":3.4,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early circulating EBV-DNA clearance predicts enhanced short-term treatment response and survival benefit in locally advanced nasopharyngeal carcinoma.","authors":"Xiameng Lu, Liru Zhu, Bibo Tan, Zhuowei Liang, Kaihua Chen, Suning Huang, Ling Li, Xiaodong Zhu","doi":"10.1186/s12885-025-14888-1","DOIUrl":"10.1186/s12885-025-14888-1","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1499"},"PeriodicalIF":3.4,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12492512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a dynamic nomogram for predicting brain metastasis in stage III NSCLC patients undergoing definitive chemoradiotherapy.","authors":"Xianyan Chen, Xi Xiao, Min Wang, Ting Mei, Ying Huang, Cheng Yi, Youling Gong","doi":"10.1186/s12885-025-14909-z","DOIUrl":"10.1186/s12885-025-14909-z","url":null,"abstract":"<p><strong>Purpose: </strong>Although survival in stage III non-small cell lung cancer (NSCLC) patients receiving concurrent chemoradiotherapy is significantly prolonged, brain metastasis (BM) remains prevalent. This study aims to develop and validate a comprehensive model for predicting BM risk in stage III NSCLC patients, guiding personalized treatment.</p><p><strong>Methods: </strong>A total of 311 patients were retrospectively analyzed and randomly divided into a training cohort (n = 230) and a validation cohort (n = 81). Univariate analysis identified potential predictors, followed by multivariate analysis using stepwise AIC regression to determine independent risk factors. A nomogram model was constructed and validated with ROC curves, calibration curves, and decision curve analysis, which was used for risk stratification.</p><p><strong>Results: </strong>Of the 311 patients, 45 (14.5%) developed BM. Key independent predictors included sex, EGFR mutation, liver metastasis, immune maintenance deficiency, neuron-specific enolase, carcinoembryonic antigen, and absolute lymphocyte count. The model demonstrated robust predictive performance, with an area under the ROC curve of 0.813 in the training cohort and 0.775 in the validation cohort, along with favorable calibration and decision curve analysis. Kaplan-Meier survival analysis showed that patients with BM had significantly shorter overall survival (43.3 vs. 75.8 months, p = 0.007). Using a nomogram-derived cutoff score of 393.79, patients were stratified into high- and low-risk groups, with the high-risk group exhibiting significantly shorter median overall survival compared to the low-risk group (p = 0.034).</p><p><strong>Conclusion: </strong>This validated nomogram offers a practical tool for early identification of high-risk patients with stage III NSCLC, facilitating personalized surveillance and intervention strategies to improve outcomes.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1500"},"PeriodicalIF":3.4,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12492854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic factors of locally advanced cervical cancer after concurrent chemoradiotherapy: a retrospective study.","authors":"Xiuying Li, Zejia Mao, Qiaoling Li, Misi He, Mingfang Guo, Hao He, Yue Huang, Qian Zheng, Ling Long, Jing Wang, Dongling Zou","doi":"10.1186/s12885-025-14691-y","DOIUrl":"10.1186/s12885-025-14691-y","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the prognostic value of magnetic resonance imaging (MRI) features and clinical features in locally advanced cervical cancer (LACC) patients after concurrent chemoradiotherapy (CCRT).</p><p><strong>Methods: </strong>A total of 189 patients with LACC who received definitive CCRT between May 2018 and December 2020 and underwent MRI, including diffusion-weighted imaging, before and 1 month after initial therapy were recruited for this study. The tumor size and mean apparent diffusion coefficient (ADC_mean) were evaluated. A Cox proportional hazards model and univariate and multivariate analyses were used to determine the associations of clinical characteristics and imaging factors with progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>The median follow-up time was 58 (range: 11-71) months. The 5-year PFS and OS rates were 73.8% and 85.5%, respectively. Univariate analysis revealed that the serum squamous cell carcinoma (SCC) antigen level, tumor stage, pretreatment tumor size, residual disease (RD) and post-treament ADC_mean were significant predictors of PFS and OS. Positive pelvic lymph node status and adjuvant chemotherapy use after CCRT were unfavorable predictive factors in terms of PFS and OS, respectively. Multivariate analysis revealed that tumor stage, SCC antigen level, and RD were independent predictors of PFS (hazard ratio [HR] = 3.282, P < 0.001; HR = 2.567, P = 0.002; and HR = 1.621, P < 0.001, respectively) and OS (HR = 2.517, P = 0.043; HR = 1.025, P = 0.015; and HR = 1.712, P = 0.008, respectively). When patients were grouped based on the cutoff values for these markers, RD size ≥ 1.1 cm was found to indicate considerably worse PFS and OS.</p><p><strong>Conclusion: </strong>Elevated SCC antigen levels, advanced tumor stage, and RD size ≥ 1.1 cm were linked to worse PFS and OS. Furthermore, the ADC_mean was not a reliable predictor of survival outcomes.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1498"},"PeriodicalIF":3.4,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12492540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A study on predicting recurrence of non-muscle-invasive bladder cancer within 2 years using mp-MRI radiomics.","authors":"Bo Chen, Yueting Zhou, Zhaojiao Li, Junhao Chen, Jieming Zuo, Haifeng Wang, Zhenhui Li, Shi Fu","doi":"10.1186/s12885-025-14753-1","DOIUrl":"10.1186/s12885-025-14753-1","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1497"},"PeriodicalIF":3.4,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world management strategies and clinical outcomes of metastatic HER2-positive breast cancer in Greece in the second-line setting and beyond (the togetHER study).","authors":"Ippokratis Korantzis, Anna Koumarianou, Vassiliki Rapti, Eleni Timotheadou, Christos Christodoulou, Dimitrios Tryfonopoulos, Sofia Karageorgopoulou, Ioannis Boukovinas, Flora Zagouri, Adamantia Nikolaidi, Konstantinos Papazisis, Evangelia Razis, Vasileios Barbounis, Athina Christopoulou, Dimitrios Mavroudis, Vassilios Georgoulias, Georgios Kesisis, Emmanuel I Papadopoulos, Rozalia Michalea, Alexandros Ardavanis","doi":"10.1186/s12885-025-14791-9","DOIUrl":"10.1186/s12885-025-14791-9","url":null,"abstract":"<p><strong>Background: </strong>In the realm of HER2-positive (HER2+) metastatic breast cancer (MBC), the advent of targeted therapies, notably trastuzumab and pertuzumab, represents a substantial advancement in enhancing patient outcomes. However, the intricacies of treatment escalate when patients encounter progression or resistance during first-line (1L) therapy. The togetHER study aimed to elucidate real-world insights into the profile, management strategies, and outcomes for HER2+ MBC patients initiating second-line treatment (2LT) in Greece, predating recent international guideline changes incorporating trastuzumab deruxtecan and tucatinib in the second line and beyond lines of treatments.</p><p><strong>Methods: </strong>Data from adult female patients with HER2+ MBC who had initiated 2LT between 01-Jan-2015 and 31-Dec-2018 in 18 oncology departments across Greece were retrospectively abstracted through medical chart review.</p><p><strong>Results: </strong>The eligible population comprised 122 patients, 68.0% of whom presented with recurrent MBC. Among the latter, 26.5% were tested for HER2 both in early and metastatic settings with 27.3% of them changing HER2 status from negative to positive. Retesting of HER2 expression following 2LT initiation was recorded in 8 cases. At 2LT initiation, patients' median age was 57.0 years and 63.6% were hormone receptor-positive. The most common metastatic sites were bone (56.6%), lung (44.3%), liver (41.0%), and brain (29.5%). Anti-HER2 agent usage in 1L and 2L stood at 91.8% and 92.6%, respectively, with rates slightly diminishing in third (3L) (85.9%) and fourth line (4L) (82.4%). Endocrine therapy administration was generally low across treatment lines (12.3%, 9.9%, and 5.9%, in 2L, 3L, and 4L respectively), while chemotherapy use increased from 30.3% in 2L to 47.9% and 47.1% to 3L and 4L, correspondingly. Median progression-free survival (PFS) for 2L, 3L, and 4L was 7.7 [95% confidence interval (CI) 6.0-14.4], 6.4 (95% CI 5.4-7.1), and 5.6 (95% CI 2.6-9.0) months, respectively, while median overall survival was 25.0 (95% CI 20.5-34.4) months.</p><p><strong>Conclusions: </strong>Although the 2LT pattern in Greece generally aligned with guidelines, persistently poor treatment outcomes underscore a significant unmet medical need for these patients.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1473"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of postoperative infection on changes in leucocyte levels in early postoperative period in patients undergoing splenectomy during cytoreductive surgery for gynaecological malignancy.","authors":"Yeşim Özkaya Uçar, Tufan Arslanca, Okan Aytekin, Gülşah Tiryaki Güner, Serpil Ünlü, Günsu Kimyon Cömert, Fatih Kılıç, Aziz Ahmet Sürel, Taner Turan","doi":"10.1186/s12885-025-14872-9","DOIUrl":"10.1186/s12885-025-14872-9","url":null,"abstract":"<p><strong>Background: </strong>In cytoreductive surgery for gynecological cancers, 13-25% of patients require splenectomy. Therefore, hematological parameters change in the post-splenectomy period, especially leucocytosis and thrombocytosis. In this study, we aimed to evaluate the changing of leucocyte and neutrophil between the groups with and without infection in the early postoperative period in patients who underwent splenectomy during cytoreductive surgery for gynecological cancer.</p><p><strong>Methods: </strong>This retrospective study included 96 patients who underwent splenectomy during cytoreductive surgery for gynecological malignancies. Leukocyte levels, CRP, procalcitonin, and platelet counts were recorded daily during the first five postoperative days. Postoperative infections were identified based on clinical and laboratory findings.</p><p><strong>Results: </strong>Postoperative infection was observed in 23 patients (24.0%). On postoperative day 4, the mean leukocyte count was 13.2±4.5 ×10³/µL in infected patients vs. 9.8±3.2 ×10³/µL in non-infected patients (p=0.01). By day 5, leukocyte levels remained significantly elevated in the infection group (p<0.05).</p><p><strong>Conclusion: </strong>Leukocyte trends, especially between days 4 and 5, may serve as a practical marker for early postoperative infection in patients undergoing splenectomy during cytoreductive surgery.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1492"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}